Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

In a report released today, Gregory Renza from RBC Capital reiterated a Buy rating on Verastem (VSTM – Research Report), with a price target of ...

Here's the scoop on the treatment, diagnosis, and definition of the primary brain lymphoma that landed Raphael in the ...

Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Lymphoma.

TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Unspecified Neurologic Disorders.

According to latest analysis by Report Ocean, the global antibody drugs market is poised to grow by USD 91 billion during 2022-2028, progressing at a CAGR of 9.7% during the forecast period. Request ...

Pope Francis meets with members of AIL (Italian Association against Leukemia, Lymphoma and Myeloma ... but St Peter’s will be the focal point, with its door opening on December 24 and closing ...

16."When I was in med school, there was a guy in his early 60s, fairly healthy, who kept coming into the hospital with vague ...

We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.

Many patients, even those with potentially curable malignancies such as large B-cell lymphoma and acute lymphoblastic B-cell leukemia, do not achieve durable remission with CAR-T-cell therapy.

The EPA has issued a final rule to phase out all uses of a harmful solvent that has been linked to liver and kidney cancer, non-Hodgkin’s lymphoma, and central nervous system damage – a chemical that ...